Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yvonne Will

Showing results (1-10 of 75) with videos related to

Pageof 8
Sort By:
Future Medicinal Chemistry|July 18, 2012
Deployment of in silico and in vitro safety assays in early-stage drug discoveryYvonne Will, Thomas Schroeter
Current Pharmaceutical Design|July 2, 2011
New insights in drug-induced mitochondrial toxicitySashi Nadanaciva, Yvonne Will
Idrugs : the Investigational Drugs Journal|October 22, 2009
The role of mitochondrial dysfunction and drug safetySashi Nadanaciva, Yvonne Will
Current Drug Targets|February 1, 2011
Investigating mitochondrial dysfunction to increase drug safety in the pharmaceutical industrySashi Nadanaciva, Yvonne Will
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 15, 2011
Evaluation of drugs with specific organ toxicities in organ-specific cell linesZhiwu Lin, Yvonne Will
Current Protocols in Toxicology|August 6, 2011
Assessment of mitochondrial toxicity in HepG2 cells cultured in high-glucose- or galactose-containing mediaRachel Swiss, Yvonne Will
Current Protocols in Toxicology|October 14, 2010
Current concepts in drug-induced mitochondrial toxicitySashi Nadanaciva, Yvonne Will
Expert Opinion on Drug Metabolism & Toxicology|July 16, 2014
Mitochondrial toxicity assessment in industry--a decade of technology development and insightYvonne Will, James Dykens
Drug Discovery Today|September 11, 2007
The significance of mitochondrial toxicity testing in drug developmentJames A Dykens, Yvonne Will
Expert Opinion on Drug Discovery|June 30, 2026
From mitochondrial signal to discovery decision: a reserve-demand framework for translational Risk assessmentGeorge W Rogers, Yvonne Will
Pageof 8

Showing results (1-10 of 75) with videos related to

Sort By:
Pageof 8
Future Medicinal Chemistry|July 18, 2012
Deployment of in silico and in vitro safety assays in early-stage drug discoveryYvonne Will, Thomas Schroeter
Current Pharmaceutical Design|July 2, 2011
New insights in drug-induced mitochondrial toxicitySashi Nadanaciva, Yvonne Will
Idrugs : the Investigational Drugs Journal|October 22, 2009
The role of mitochondrial dysfunction and drug safetySashi Nadanaciva, Yvonne Will
Current Drug Targets|February 1, 2011
Investigating mitochondrial dysfunction to increase drug safety in the pharmaceutical industrySashi Nadanaciva, Yvonne Will
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 15, 2011
Evaluation of drugs with specific organ toxicities in organ-specific cell linesZhiwu Lin, Yvonne Will
Current Protocols in Toxicology|August 6, 2011
Assessment of mitochondrial toxicity in HepG2 cells cultured in high-glucose- or galactose-containing mediaRachel Swiss, Yvonne Will
Current Protocols in Toxicology|October 14, 2010
Current concepts in drug-induced mitochondrial toxicitySashi Nadanaciva, Yvonne Will
Expert Opinion on Drug Metabolism & Toxicology|July 16, 2014
Mitochondrial toxicity assessment in industry--a decade of technology development and insightYvonne Will, James Dykens
Drug Discovery Today|September 11, 2007
The significance of mitochondrial toxicity testing in drug developmentJames A Dykens, Yvonne Will
Expert Opinion on Drug Discovery|June 30, 2026
From mitochondrial signal to discovery decision: a reserve-demand framework for translational Risk assessmentGeorge W Rogers, Yvonne Will
Pageof 8